Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2019 4
2020 6
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells.
Wu ZX, Peng Z, Yang Y, Wang JQ, Teng QX, Lei ZN, Fu YG, Patel K, Liu L, Lin L, Zou C, Chen ZS. Wu ZX, et al. Front Oncol. 2020 May 12;10:674. doi: 10.3389/fonc.2020.00674. eCollection 2020. Front Oncol. 2020. PMID: 32477940 Free PMC article.
Multi-dose oral abuse deterrent formulation of loperamide using hot melt extrusion.
Nukala PK, Palekar S, Patki M, Fu Y, Patel K. Nukala PK, et al. Among authors: fu y. Int J Pharm. 2019 Oct 5;569:118629. doi: 10.1016/j.ijpharm.2019.118629. Epub 2019 Aug 16. Int J Pharm. 2019. PMID: 31425818
Folate Receptor-Targeted Albumin Nanoparticles Based on Microfluidic Technology to Deliver Cabazitaxel.
Meng F, Sun Y, Lee RJ, Wang G, Zheng X, Zhang H, Fu Y, Yan G, Wang Y, Deng W, Parks E, Kim BYS, Yang Z, Jiang W, Teng L. Meng F, et al. Among authors: fu y. Cancers (Basel). 2019 Oct 16;11(10):1571. doi: 10.3390/cancers11101571. Cancers (Basel). 2019. PMID: 31623082 Free PMC article.
Process optimization of twin-screw melt granulation of fenofibrate using design of experiment (DoE).
Mamidi HK, Palekar S, Nukala PK, Mishra SM, Patki M, Fu Y, Supner P, Chauhan G, Patel K. Mamidi HK, et al. Among authors: fu y. Int J Pharm. 2021 Jan 25;593:120101. doi: 10.1016/j.ijpharm.2020.120101. Epub 2020 Dec 10. Int J Pharm. 2021. PMID: 33309834
Nanoformulation of PROteolysis TArgeting Chimera targeting 'undruggable' c-Myc for the treatment of pancreatic cancer.
Saraswat A, Patki M, Fu Y, Barot S, Dukhande VV, Patel K. Saraswat A, et al. Among authors: fu y. Nanomedicine (Lond). 2020 Aug;15(18):1761-1777. doi: 10.2217/nnm-2020-0156. Epub 2020 Jul 23. Nanomedicine (Lond). 2020. PMID: 32698663
Efavirenz nanomicelles loaded vaginal film (EZ film) for preexposure prophylaxis (PrEP) of HIV.
Patki M, Vartak R, Jablonski J, Mediouni S, Gandhi T, Fu Y, Cetindag E, Dave R, Valente ST, Patel K. Patki M, et al. Among authors: fu y. Colloids Surf B Biointerfaces. 2020 Oct;194:111174. doi: 10.1016/j.colsurfb.2020.111174. Epub 2020 Jun 6. Colloids Surf B Biointerfaces. 2020. PMID: 32540766
EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma.
Fu Y, Rathod D, Abo-Ali EM, Dukhande VV, Patel K. Fu Y, et al. Pharmaceutics. 2019 Oct 1;11(10):504. doi: 10.3390/pharmaceutics11100504. Pharmaceutics. 2019. PMID: 31581483 Free PMC article.
Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.
Fu Y, Rathod D, Patel K. Fu Y, et al. Exp Cell Res. 2020 Nov 1;396(1):112275. doi: 10.1016/j.yexcr.2020.112275. Epub 2020 Sep 6. Exp Cell Res. 2020. PMID: 32898554
β-cyclodextrin polymer/Soluplus® encapsulated Ebselen ternary complex (EβpolySol) as a potential therapy for vaginal candidiasis and pre-exposure prophylactic for HIV.
Vartak R, Patki M, Menon S, Jablonski J, Mediouni S, Fu Y, Valente ST, Billack B, Patel K. Vartak R, et al. Among authors: fu y. Int J Pharm. 2020 Sep 8;589:119863. doi: 10.1016/j.ijpharm.2020.119863. Online ahead of print. Int J Pharm. 2020. PMID: 32911046
BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation.
Rathod D, Fu Y, Patel K. Rathod D, et al. Among authors: fu y. Eur J Pharm Sci. 2019 Oct 1;138:105039. doi: 10.1016/j.ejps.2019.105039. Epub 2019 Aug 5. Eur J Pharm Sci. 2019. PMID: 31394259
13 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback